DRUG — Bright Minds Biosciences Inc.
7 mentions in the last 24 hours · 0.05% of all mentions
Why people talked about DRUG (2026-11-02)
- The FDA issued a partial clinical hold on the Phase 2 trial of BMB-101 for epileptic encephalopathies.
- The regulatory action was taken due to observed mouse toxicity and gaps in pediatric data.
- Trading for Bright Minds Biosciences was halted and subsequently resumed with shares opening significantly lower.
| Bluesky | 5 | community |
| GDELT | 2 | news |